Search Thermo Fisher Scientific
- Contact Us
- Quick Order
-
Don't have an account ? Create Account
Search Thermo Fisher Scientific
Vaccines are specialized preparations that prime the body’s immune response to respond rapidly to infectious diseases. They do so by exposing the body to components of the pathogen that elicit and remember antibodies that can neutralize the pathogen. The immune system recognizes the antigen as foreign and generates an immune response which ultimately results in the production of neutralizing antibodies against the antigen. This “memory” of the pathogen is developed and retained in the form of memory cells which accelerates the immune response during a future exposure of the body to the actual, disease-causing pathogen.
There are a wide variety of vaccine strategies, which have evolved in complexity over time. First vaccines were generated in the format of live attenuated pathogens (ex. MMR vaccine), inactivated viruses (ex. polio vaccine), subunit vaccines (ex. Hepatitis B vaccine), and virus-like particles (VLPs) (ex. Human papillomavirus VLP vaccine). Taking advantage of technologies developed over the first part of this century, new vaccines formats like viral vector vaccines, and mRNA vaccines (ex. Pfizer-BioNTech, Moderna Covid-19 vaccines) were matured into regular use during the SARS-Cov-2 pandemic. Cryo-electron microscopy is playing a crucial role in expediting the vaccine design and discovery process.
To accelerate the development of vaccines that are both safe and effective, it is crucial to use imaging methods that offer comprehensive structural data throughout the vaccine discovery and development process. Cryo-electron microscopy (cryo-EM) is a powerful tool for determining 3D structures and is enabling the optimization of vaccine design and development pipelines. Cryo-EM can also be used effectively for lipid nanoparticle characterization throughout the vaccine development, formulation, and manufacturing process.
One of the major challenges to develop vaccines against infectious diseases such as RSV and HIV is the design of an effective antigen. Cryo-EM supports successful vaccine design by:
Transmission electron microscopy is an important technique for characterizing attributes of all vaccine classes. At room temperature, imaging of inactivated and attenuated viruses and with adjuvant is common. For more advanced vaccine formats, such as liposomes, lipid nanoparticles (LNPs), VLPs and inorganic nanoparticles, cryo-EM based particle characterization ensures unbiased direct assessment of size, morphology, particle integrity, encapsulation state, and the stability of a vaccine formulation.
Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infection and death amongst infants and elderly. Worldwide, about 118,200 children die annually from RSV. Cryo-EM has played a crucial role in the development of RSV vaccines. The prefusion conformation of the RSV fusion (F) glycoprotein is a key immunogen for vaccine development. Cryo-EM based structural biology helped solve the structure of RSV nucleocapsid like assemblies, providing information on the virus architecture. Furthermore, the cryo-EM structure of a prefusion-stabilized RSV antigen (F protein) contributed to the design of effective RSV vaccine candidates.
Recommended further reading:
Some of the vaccines format require a delivery vehicle to ensure safe and targeted delivery of the vaccine's antigen. Liposomes, lipid nanoparticles (LNPs), virus-like particles (VLPs), and inorganic nanoparticles are few such delivery vehicles. To read more about viral vector-based delivery vehicles, which are also extensively leveraged in cell and gene therapy, see more detailed information on cryo-EM for cell and gene therapy. Below we focus on LNPs, a non-viral vector-based vaccine delivery vehicle. Note that due to their ability to encapsulate a wide range of materials and their targetability, LNPs are also in the development for therapeutic applications like delivering vehicles for gene therapy and gene editing.
LNPs are small, spherical, lipid-based structures often ranging from 20 to 200 nanometers in size. They are of significant interest due to their ability to accommodate various types of genetic material to deliver it to target cells or tissue with specificity. Stimulated by the recent success of LNPs in COVID-related vaccines, there is wide interest and activity in developing LNP-based vaccines to target other infectious and non-infectious diseases, such as cancer and cardiovascular disease.
The successful design and application of LNPs depend heavily on their structural and morphological properties as they are directly related to their function. The safety and efficacy of LNPs are directly correlated to their size and morphology. Selection of the core structural components of LNPs can affect the structure and function of Lipid nanoparticles. Furthermore, external conditions such as buffer, temperature, and pH, the manufacturing process, storage conditions also affect the size and morphology of LNPs.
There are 5 major components of a therapeutic LNP: ionizable lipids, helper phospholipids, cholesterol, PEG lipids and, of course, the therapeutic (typically nucleic acid) to be delivered. Changes in any of these components, identify or ratio, will have a direct effect on LNP properties.
Due to their susceptibility to wide range of components as mentioned above, regulatory agencies around the world ask for comprehensive sample characterization to study the critical quality attributes (QCA) using multiple techniques to ensure the safety and effectiveness of a vaccine formulation. Cryo-EM is the only technology that offers direct visualization of LNP with nanometer-scale resolution. Furthermore, lipid nanoparticles are complex systems that require multiple techniques to characterize several parameters, cryo-EM offers to characterize several properties of LNP samples from a single experiment.
Multiple quality attributes of LNP formulation can be characterized from a single cryo-EM dataset.
Quality Attributes | Cryo-EM |
---|---|
Shape and size distribution |
•
|
Morphology and lamellarity |
• |
Cargo containing vs empty particles |
• |
Particle integrity |
• |
Core (internal) morphology |
• |
Impurities |
• |
Aggregation |
• |
Lipoplex vs LNPs |
• |
Vaccine immunogenicity refers to a vaccine's potential to stimulate an immune response. To evaluate this potential, pre-clinical immunogenicity studies are carried out on animals such as mice, rabbits, and monkeys. These studies help identify the most promising candidates and determine the optimal doses and schedules for the vaccine.
Cryo-EM supports the study of the structural basis of the immune response against immunogens. Detailed structural analysis reveals precise binding sites of both neutralizing and non-neutralizing antibodies generated against the immunogen. This information not only helps to understand the immunogenicity potential of an antigen but also offers to engineer the immunogen to increase its immunogenicity.
Cryo-EM PEM (or EMPEM) is growing in popularity to study the immune response (immunogenicity) against biologics such as antibodies and vaccines. This technology allows the study of the polyclonal antibody response against an immunogen/vaccine candidate. With cryo-EM, it is possible to unambiguously characterize the epitope-paratope interaction at a level at which amino acid side chains and their interactions are observable. With this information, it is possible to optimize desirable immunogenicity for vaccine design or reduce the immunogenicity for antibody therapeutics and gene therapy viral vectors.
Cryo-EM Polyclonal Epitope mapping (cryoEMPEM) workflow
Recommended further reading:
1) Structural mapping of antibody landscapes to human betacoronavirus spike proteins, Science Advances (2022).
2) Mapping Polyclonal Antibody Responses in Non-human Primates Vaccinated with HIV Env Trimer Subunit Vaccines, Cell Reports (2020).
3) Polyclonal antibody responses to HIV Env immunogens resolved using cryoEM, Nature Communications (2021).
Our full cryo-TEM portfolio features state-of-the-art technology with a range of automation features designed to extend accessibility, reduce the need for user intervention, and enable easy organization, viewing, and sharing data.
For Research Use Only. Not for use in diagnostic procedures.